6/10/2023

Janusmed kön och genus

Janusmed kön och genus – FLAGYL Comp. emätinpuikko

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
B B
B B

Nystatin

Nystatin

Klass: B

Visa all info

Skriv ut

Kontakta oss

Produkter

Visa alla produkter

Adiclair, Biofanal, FLAGYL Comp. emätinpuikko, Mycostat......

Adiclair, Biofanal, FLAGYL Comp. emätinpuikko, Mycostatin, Mykundex Mono Salbe, Nystaderm, Nystatin Abacus Medicine, Nystatin Orifarm, Nystatin acis, Nystatin fem JENAPHARM, Nystimex, Nyvigan
ATC-koder

A07AA02, D01AA01, G01AA01, G01AF01

A07AA02, D01AA01, G01AA01, G01AF01
Substanser

nystatin

nystatin
Sammanfattning

Det saknas publicerade kontrollerade studier om skillnader mellan könen avseende effekt, säkerhet och farmakokinetik för nystatin.

Det saknas publicerade kontrollerade studier om skillnader mellan könen avseende effekt, säkerhet och farmakokinetik för nystatin.
Background

Pharmacokinetics and dosing
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of nystatin have been found.

Effects
No studies with a clinically relevant sex analysis regarding the effects of nystatin have been found.

Adverse effects
No studies with a clinically relevant sex analysis regarding adverse effects of nystatin have been found.

Reproductive health issues
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Other information
In some countries, nystatin is available as vaginal preparations. They may damage latex contraceptives and thus additional contraceptives may be needed [1].

# Pharmacokinetics and dosing No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of nystatin have been found. # Effects No studies with a clinically relevant sex analysis regarding the effects of nystatin have been found. # Adverse effects No studies with a clinically relevant sex analysis regarding adverse effects of nystatin have been found. # Reproductive health issues Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan). # Other information In some countries, nystatin is available as vaginal preparations. They may damage latex contraceptives and thus additional contraceptives may be needed [1].
Försäljning på recept

Visa hela försäljning på recept

Fler kvinnor än män hämtade ut läkemedel innehållande nystatin (ATC-kod A07AA02) på recept i Sverige år 2015, totalt 37 150 kvinnor och 20 191 män. Det motsvarar 7,6 respektive 4,1 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 80 år och äldre hos båda könen. I genomsnitt var läkemedel innehållande nystatin 1,8 gånger vanligare hos kvinnor [2].
Referenser

Visa referenser

  1. Martindale: The Complete Drug Reference. Pharmaceutical Press.

  2. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.]

  1. Martindale: The Complete Drug Reference. Pharmaceutical Press.
  2. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.]
Uppdaterat

Litteratursökningsdatum 6/2/2015

Litteratursökningsdatum 6/2/2015
A A
A A

Metronidazol – lokalt

Metronidazol – lokalt

Klass: A

Visa all info

Skriv ut

Kontakta oss

Produkter

Visa alla produkter

FLAGYL Comp. emätinpuikko, Flagyl, Metronidazol 2care4,......

FLAGYL Comp. emätinpuikko, Flagyl, Metronidazol 2care4, Robaz, Rosazol, Rozex, Zidoval
ATC-koder

D06BX01, G01AF01

D06BX01, G01AF01
Substanser

metronidazol, metronidazolbensoat

metronidazol, metronidazolbensoat
Sammanfattning

En studie av metronidazol gel vid rosacea visade likartad effekt hos kvinnor och män.

En studie av metronidazol gel vid rosacea visade likartad effekt hos kvinnor och män.
Background

Pharmacokinetics and dosing
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of topical metronidazole have been found. No difference between men and women has been shown for transdermal absorption in general [1].

Effects
In an open-label community-based study (145 men, 437 women) investigating the responsiveness to twice-daily application of metronidazole topical gel 0.75% in subjects with rosacea, the efficacy in reducing lesion count and improving rosacea severity was equivalent in men and women [2]. A small study of patients with mild or moderate papulopustular rosacea (7 men, 25 women) showed that 8 weeks treatment with topical metronidazole or terbinafine yielded similar effect in men and women [3]. Rosacea is a common chronic facial skin disease in which women are approximately 2-3 times more likely than men to be affected [4].

Adverse effects
No studies with a clinically relevant sex analysis regarding adverse effects of topical metronidazole have been found.

Reproductive health issues
Regarding teratogenic aspects, please co......

Visa hela bakgrundstexten

# Pharmacokinetics and dosing No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of topical metronidazole have been found. No difference between men and women has been shown for transdermal absorption in general [1]. # Effects In an open-label community-based study (145 men, 437 women) investigating the responsiveness to twice-daily application of metronidazole topical gel 0.75% in subjects with rosacea, the efficacy in reducing lesion count and improving rosacea severity was equivalent in men and women [2]. A small study of patients with mild or moderate papulopustular rosacea (7 men, 25 women) showed that 8 weeks treatment with topical metronidazole or terbinafine yielded similar effect in men and women [3]. Rosacea is a common chronic facial skin disease in which women are approximately 2-3 times more likely than men to be affected [4]. # Adverse effects No studies with a clinically relevant sex analysis regarding adverse effects of topical metronidazole have been found. # Reproductive health issues Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Försäljning på recept

Visa hela försäljning på recept

Fler kvinnor än män hämtade ut kräm/gel innehållande metronidazol (ATC-kod D06BX01) på recept i Sverige år 2015, totalt 14 287 kvinnor och 7329 män. Det motsvarar 2,9 respektive 1,5 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 70-79 år hos båda könen. I genomsnitt var kräm/gel innehållande metronidazol 2,4 gånger vanligare hos kvinnor [4].
Referenser

Visa referenser

  1. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-21.

  2. Wolf JE, Del Rosso JQ. The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. Cutis. 2007;79:73-80.

  3. Serdar ZA, Yaşar Ş. Efficacy of 1% terbinafine cream in comparison with 075% metronidazole gel for the treatment of papulopustular rosacea. Cutan Ocul Toxicol. 2011;30:124-8.

  4. Blount BW, Pelletier AL. Rosacea: a common, yet commonly overlooked, condition. Am Fam Physician. 2002;66:435-40.

  5. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2017-01-26.]

  1. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-21.
  2. Wolf JE, Del Rosso JQ. The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. Cutis. 2007;79:73-80.
  3. Serdar ZA, Yaşar Ş. Efficacy of 1% terbinafine cream in comparison with 075% metronidazole gel for the treatment of papulopustular rosacea. Cutan Ocul Toxicol. 2011;30:124-8.
  4. Blount BW, Pelletier AL. Rosacea: a common, yet commonly overlooked, condition. Am Fam Physician. 2002;66:435-40.
  5. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2017-01-26.]
Uppdaterat

Litteratursökningsdatum 1/17/2017

Litteratursökningsdatum 1/17/2017